Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • STAT
    (4)
  • Apoptosis
    (2)
  • JAK
    (2)
  • NF-κB
    (2)
  • Antioxidant
    (1)
  • DNA/RNA Synthesis
    (1)
  • OCT
    (1)
  • p38 MAPK
    (1)
  • Others
    (1)
Filter
Search Result
Results for "

stat-3-in-1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    5
    TargetMol | Inhibitors_Agonists
  • Natural Products
    2
    TargetMol | Natural_Products
  • Recombinant Protein
    2
    TargetMol | Recombinant_Protein
STAT3-IN-1
T130092059952-75-7
STAT3-IN-1 selective and orally active inhibitor of STAT3(in HT29 and MDA-MB 231 cells, with IC50 values of 1.82 μM and 2.14 μM , respectively), induces tumor apoptosis.
  • Inquiry Price
Size
QTY
Dual Cathepsin L/JAK-IN-1
T2050412450279-41-9
DualCathepsinL JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1 2 3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL JAK-IN-1 is applicable in research on acute lung injury (ALI).
  • Inquiry Price
10-14 weeks
Size
QTY
15(R)-Lipoxin A4
15(R)-Lipoxin A4,AT-Lipoxin A4
T37265171030-11-8
Lipid-derived lipoxins are produced at the site of vascular and mucosal inflammation where they down-regulate polymorphonuclear leukocyte recruitment and function. 15(R)-Lipoxin A4 (15(R)-LXA4) is derived from the aspirin-triggered formation of 15(R)-HETE from arachidonic acid. [1] [2] 15(R)-LXA4 inhibits LTB4-induced chemotaxis, adherence, and transmigration of neutrophils with twice the potency of LXA4 demonstrating activity in the nM range.[2] [3] The anti-inflammatory effects of aspirin may be ascribed in part to the ability of 15(R)-LXA4 to regulate leukocyte function.[4] 15(R)-LXA4 is reported to promote resolution of inflammation in LPS-treated stromal cells derived from intermediate-stage diseased supraspinatus tendons as evidenced by increased expression of the STAT-6 pathway target genes, ALOX15 and CD206.[5]
  • Inquiry Price
10-14 weeks
Size
QTY
Curculigoside
Curculigoside A
T6S196685643-19-2
1. Curculigoside (Curculigoside A) can prevent bone loss , improve osteogenesis and inhibit osteoclastogenesis of hAFSCs, suggesting its potential use to regulate hAFSC osteogenic differentiation for treating bone disorders. 2. Curculigoside can promote calcium deposition and increase the levels of ALP and Runx2 in osteoblasts under oxidative stress via anti-oxidative character. 3. Curculigoside possesses potent antioxidant properties against oxidative stress insults. can protect endothelial cells against oxidative injury induced by H2O2, suggesting that this compound may constitute a promising intervention against cardiovascular disorders.
  • Inquiry Price
Size
QTY
3-O-Methylgallic acid
3,4-Dihydroxy-5-methoxybenzoic acid
TN12373934-84-7
3-O-Methylgallic acid (3,4-Dihydroxy-5-methoxybenzoic acid) reduces cell proliferation in Caco-2 cells (IC50 = 24.1 μM) more effectively than anthocyanins and may offer protection against colon cancer after its formation in the gut. It inhibits transcription factors NF-κB, AP-1, STAT-1, and OCT-1, which are known to be activated in colorectal cancer.
  • Inquiry Price
Size
QTY